Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline
-
Letto da:
-
Di:
In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD (Henry Ford Hospital), and Nancy Reau, MD (Rush University Medical Center), are joined by Tatyana Kushner, MD (Weill Cornell Medicine), to discuss hepatitis delta virus (HDV).
Topics covered:
Why fewer than 10% of HBsAg-positive patients have ever been tested for HDV — and why that needs to change
The diagnostic cascade from HDV antibody to HDV RNA, and barriers to reflex testing implementation
The recent FDA approval of bulevirtide (Livdelzi) for chronic HDV infection, including dosing, administration, and the combination vs. monotherapy question
10 mg vs. 2 mg dose considerations and off-treatment response data
Phase 3 pipeline
For more: https://www.hcplive.com/view/liver-lineup-hdv-diagnosis-bulevirtide-and-the-delta-pipeline